FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312184411> ?p ?o ?g. }

• W4312184411 endingPage "S12" @default.
• W4312184411 startingPage "S12" @default.
• W4312184411 abstract "Discoidin Domain Receptor 2 (DDR2) is a tyrosine kinase receptor which binds fibrillar collagen type 1. Previous work from our lab demonstrated that genetic inactivation of DDR2 increases sensitivity to olaparib in homologous recombination (HR) proficient ovarian cancer models through induced HR deficiency and decreased pentose phosphate pathway activation. This leads to decreased nucleotide biosynthesis and increased DNA damage. This study aimed to demonstrate increased sensitivity to olaparib with pharmacologic inhibition of DDR2 and to further understand the cell signaling mechanism of DDR2 inhibition increasing sensitivity to olaparib. Two high grade serous HR proficient ovarian cancer cell lines were used, ES2 and UWB1 with genetic re-expression of BRCA1 (UWB1 BRCA1wt). A small molecule allosteric inhibitor of DDR2 was used for pharmacologic inhibition. Western blot was used to detect changes in HR pathway protein expression after DDR2 inhibition. Cell viability after treatment with or without 1 μM of the DDR2 inhibitor and olaparib was quantified using MTS assays. Flow cytometry was used to quantify cell cycle changes relative to DDR2 expression. Western blot confirmed both cell lines expressed DDR2 and showed decreased expression of p-DDR2 and p-AKT, a downstream effector, after treatment with the DDR2 inhibitor thus confirming that the inhibitor inhibits the DDR2 pathway. MTS viability assays showed no cell death with inhibitor treatment alone. However, treatment with the DDR2 inhibitor increased sensitivity to olaparib with a 99% reduction (0.03 μM vs 42 μM) and 14% reduction (122 μM vs 141 μM) in IC50 in ES2 and UWB1 BRCA1wt cell lines, respectively. Notably, the DDR2 inhibitor altered expression of proteins involved in DNA damage repair. We found decreased expression of ATM, a known inducer of the pentose phosphate pathway, and decreased expression of p-CHK1, a key regulator of S phase progression. Cell cycle changes using flow cytometry showed genetic inhibition of DDR2 increased the length of S phase in both ES2 and UWB1 BRCA1wt cells. Finally, DDR2 inhibition did not change the expression of PARP1 (poly(ADP ribose) polymerase 1) but did decrease PARylation, a posttranslational modification of proteins catalyzed by PARP, suggesting that DDR2 inhibition impairs PARP1 activity. Pharmacologic inhibition of DDR2 increases sensitivity to olaparib in HR proficient ovarian cancer models through impaired DNA damage repair by decreasing pentose phosphate pathway activation, disrupting cell cycle regulation and impairing PARP1 activity. This adds to prior evidence that genetic inactivation of DDR2 induces functional HR deficiency and increases DNA damage. Taken together, these results provide strong evidence in support of DDR2 inhibition as a therapeutic target for HR proficient ovarian cancers." @default.
• W4312184411 created "2023-01-04" @default.
• W4312184411 creator A5002033312 @default.
• W4312184411 creator A5003854163 @default.
• W4312184411 creator A5009822037 @default.
• W4312184411 creator A5024497385 @default.
• W4312184411 creator A5027513211 @default.
• W4312184411 creator A5028809625 @default.
• W4312184411 creator A5030433779 @default.
• W4312184411 creator A5031718333 @default.
• W4312184411 creator A5031989490 @default.
• W4312184411 creator A5038806823 @default.
• W4312184411 creator A5048543587 @default.
• W4312184411 creator A5052042209 @default.
• W4312184411 creator A5068154333 @default.
• W4312184411 creator A5076087889 @default.
• W4312184411 creator A5087555784 @default.
• W4312184411 creator A5088714641 @default.
• W4312184411 date "2022-12-01" @default.
• W4312184411 modified "2023-09-27" @default.
• W4312184411 title "26 Pharmacologic inhibition of discoidin domain receptor 2 (DDR2) sensitizes homologous recombination proficient ovarian cancer models to treatment with olaparib" @default.
• W4312184411 doi "https://doi.org/10.1016/s2352-5789(22)00238-7" @default.
• W4312184411 hasPublicationYear "2022" @default.
• W4312184411 type Work @default.
• W4312184411 citedByCount "0" @default.
• W4312184411 crossrefType "journal-article" @default.
• W4312184411 hasAuthorship W4312184411A5002033312 @default.
• W4312184411 hasAuthorship W4312184411A5003854163 @default.
• W4312184411 hasAuthorship W4312184411A5009822037 @default.
• W4312184411 hasAuthorship W4312184411A5024497385 @default.
• W4312184411 hasAuthorship W4312184411A5027513211 @default.
• W4312184411 hasAuthorship W4312184411A5028809625 @default.
• W4312184411 hasAuthorship W4312184411A5030433779 @default.
• W4312184411 hasAuthorship W4312184411A5031718333 @default.
• W4312184411 hasAuthorship W4312184411A5031989490 @default.
• W4312184411 hasAuthorship W4312184411A5038806823 @default.
• W4312184411 hasAuthorship W4312184411A5048543587 @default.
• W4312184411 hasAuthorship W4312184411A5052042209 @default.
• W4312184411 hasAuthorship W4312184411A5068154333 @default.
• W4312184411 hasAuthorship W4312184411A5076087889 @default.
• W4312184411 hasAuthorship W4312184411A5087555784 @default.
• W4312184411 hasAuthorship W4312184411A5088714641 @default.
• W4312184411 hasBestOaLocation W43121844111 @default.
• W4312184411 hasConcept C101544691 @default.
• W4312184411 hasConcept C104317684 @default.
• W4312184411 hasConcept C153911025 @default.
• W4312184411 hasConcept C182979987 @default.
• W4312184411 hasConcept C184235292 @default.
• W4312184411 hasConcept C2776305115 @default.
• W4312184411 hasConcept C2779138821 @default.
• W4312184411 hasConcept C2779962180 @default.
• W4312184411 hasConcept C502942594 @default.
• W4312184411 hasConcept C55493867 @default.
• W4312184411 hasConcept C71924100 @default.
• W4312184411 hasConcept C82381507 @default.
• W4312184411 hasConcept C86803240 @default.
• W4312184411 hasConcept C95444343 @default.
• W4312184411 hasConceptScore W4312184411C101544691 @default.
• W4312184411 hasConceptScore W4312184411C104317684 @default.
• W4312184411 hasConceptScore W4312184411C153911025 @default.
• W4312184411 hasConceptScore W4312184411C182979987 @default.
• W4312184411 hasConceptScore W4312184411C184235292 @default.
• W4312184411 hasConceptScore W4312184411C2776305115 @default.
• W4312184411 hasConceptScore W4312184411C2779138821 @default.
• W4312184411 hasConceptScore W4312184411C2779962180 @default.
• W4312184411 hasConceptScore W4312184411C502942594 @default.
• W4312184411 hasConceptScore W4312184411C55493867 @default.
• W4312184411 hasConceptScore W4312184411C71924100 @default.
• W4312184411 hasConceptScore W4312184411C82381507 @default.
• W4312184411 hasConceptScore W4312184411C86803240 @default.
• W4312184411 hasConceptScore W4312184411C95444343 @default.
• W4312184411 hasLocation W43121844111 @default.
• W4312184411 hasOpenAccess W4312184411 @default.
• W4312184411 hasPrimaryLocation W43121844111 @default.
• W4312184411 hasRelatedWork W2147619880 @default.
• W4312184411 hasRelatedWork W2561005546 @default.
• W4312184411 hasRelatedWork W2973954290 @default.
• W4312184411 hasRelatedWork W3023457002 @default.
• W4312184411 hasRelatedWork W3121450744 @default.
• W4312184411 hasRelatedWork W4320724591 @default.
• W4312184411 hasRelatedWork W4362493060 @default.
• W4312184411 hasRelatedWork W4362493204 @default.
• W4312184411 hasRelatedWork W4362495229 @default.
• W4312184411 hasRelatedWork W4381955958 @default.
• W4312184411 hasVolume "44" @default.
• W4312184411 isParatext "false" @default.
• W4312184411 isRetracted "false" @default.
• W4312184411 workType "article" @default.